Oric Pharmaceuticals/$ORIC
1D1W1MYTD1Y5YMAX
Capital at risk
About Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
- Ticker
- $ORIC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 111
- Headquarters
- South San Francisco, United States
- Website
- www.oricpharma.com
ORIC Metrics
BasicAdvanced
$1.3B
-
-$1.35
0.99
-
Price and volume
Market cap
$1.3B
Beta
0.99
52-week high
$14.93
52-week low
$7.23
Average daily volume
1.4M
Financial strength
Current ratio
13.186
Quick ratio
12.756
Long term debt to equity
0.007
Total debt to equity
0.016
Profitability
EBITDA (TTM)
-154.995
Management effectiveness
Return on assets (TTM)
-25.97%
Return on equity (TTM)
-39.80%
Valuation
Price to book
3.4
Price to tangible book (TTM)
3.4
Price to free cash flow (TTM)
-11.584
Free cash flow yield (TTM)
-8.63%
Free cash flow per share (TTM)
-1.081
Growth
Earnings per share change (TTM)
-28.52%
3-year earnings per share growth (CAGR)
-14.64%
What the Analysts think about ORIC
Analyst ratings (Buy, Hold, Sell) for Oric Pharmaceuticals stock.
Analyst projections of the future price of Oric Pharmaceuticals stock.
Bulls say / Bears say
ORIC has moved rinzimetostat into the global Phase 3 Himalayas-1 trial after discussions with the FDA and other health authorities. Bayer is supplying darolutamide at no cost for the study, while ORIC keeps global rights to its drug. (ORIC Pharmaceuticals)
Early Phase 1b data for rinzimetostat showed an 84% five-month landmark radiographic progression-free survival rate, with mostly Grade 1 treatment-related adverse events, one Grade 3 event and no drug-related Grade 4 or 5 events. That combination suggests a possible efficacy and tolerability advantage, although the Phase 3 trial still needs to confirm it. (ORIC Pharmaceuticals)
ORIC ended the second quarter with $387.6 million in cash and investments and expects funding to last into the second half of 2028, beyond the anticipated first Phase 3 readout. Its second programme, enozertinib, also has lung-cancer data due in the second half of 2026, offering another potential catalyst. (ORIC Pharmaceuticals)
ORIC remains pre-revenue and its second-quarter net loss widened to $41.5 million, while first-half net loss reached $77.3 million. Cash fell from $419.7 million at the end of March to $387.6 million at the end of June, and the company has already raised money through its ATM facility, highlighting ongoing dilution risk. (RTTNews, ORIC Pharmaceuticals)
The main value driver is still years from a definitive result: ORIC expects the primary endpoint readout from Himalayas-1 in the first half of 2028, while enozertinib remains in Phase 1b. Investors therefore face a long period of clinical, regulatory and financing risk before any product revenue is possible. (RTTNews, ORIC Pharmaceuticals)
The encouraging rinzimetostat evidence remains immature: the company’s reported progression-free-survival figures were based on a median follow-up of only 4.9 months and came before any Phase 3 result. Durability and comparative benefit against the trial’s control arm therefore remain unproven. (ORIC Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 27 Sept 2026.
ORIC Financial Performance
Revenues and expenses
ORIC Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ORIC
AllUSDGBPEUR
Fund name | Fund size | $ORIC weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.09% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.